Gabather AB (GABA) AI Stock Analysis

0 Followers

Gabather AB

(Nasdaq OMX AB:GABA)

Select Model

Rating:39Underperform

Price Target:SEK 0.02▼(-10.00% Downside)

Action:downgraded

Date:11/11/26

The score is driven primarily by weak financial performance: no revenue, continued losses, and material negative free cash flow imply ongoing financing dependence despite a debt-free balance sheet and some improvement in burn. Technicals add pressure with price below key moving averages and negative MACD, while valuation metrics provide little support given the negative P/E and no dividend.

Positive Factors

Debt-Free Balance SheetA debt-free balance sheet avoids contractual interest costs and reduces creditor pressure, giving Gabather greater flexibility while it funds CNS drug development. This is a durable financial advantage, although it does not remove the need for operating capital.

Negative Factors

No Demonstrated RevenueZero revenue means Gabather has not yet established commercial product sales or an operating revenue base to fund research internally. This leaves future progress dependent on successful development, partnering, or financing rather than recurring business cash inflows.

Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 11.60M
Dividend Yield: ―
Average Volume (3M): 2.48M
Price to Earnings (P/E): -1.2
Beta (1Y): 0.80
Revenue Growth: ―
EPS Growth: 65.27%
Country: Sweden
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorder...

Gabather AB Financial Statement Overview

Summary

Financials reflect a pre-revenue company with persistent operating and net losses and ongoing cash burn (TTM operating/free cash flow ~-7.1M). The key positive is no reported debt, and losses/cash burn have improved versus prior years, but equity has been volatile (including negative in 2024–2025) and the business remains dependent on external funding without demonstrated revenue traction.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-4.90M	-4.53M	0	37.00K	3,000	-16.91M
Net Income	-5.00M	-4.65M	-7.75M	-9.44M	-8.54M	-17.00M
Balance Sheet
Total Assets	4.54M	3.83M	1.83M	7.36M	6.75M	15.39M
Cash, Cash Equivalents and Short-Term Investments	3.69M	3.14M	878.00K	1.11M	6.27M	14.85M
Total Debt	0	0	0	0	0	0
Total Liabilities	3.08M	4.69M	6.01M	6.88M	3.31M	4.43M
Stockholders Equity	1.46M	-863.00K	-4.17M	486.00K	3.44M	10.96M
Cash Flow
Free Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Operating Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	7.82M	9.49M	3.09M	6.49M	1.02M	46.00K

Gabather AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.02

Price Trends

50DMA0.02Negative

100DMA0.03Negative

200DMA0.03Negative

Market Momentum

MACD-0.00Negative

RSI43.81Neutral

STOCH37.50Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.81 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.

Gabather AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:GABA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	78Outperform	SEK 43.75B	58.03	16.50%	―	2.96%	-4.07%
SE:SANION	77Outperform	SEK 1.66B	8.96	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 27.56B	263.87	5.18%	0.68%	-46.09%	-90.13%
SE:ALZCUR	55Neutral	SEK 890.82M	44.74	65.99%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ORX	41Neutral	SEK 377.97M	-0.10	-115.03%	―	-97.68%	-83.26%
SE:GABA	39Underperform	SEK 11.60M	-1.20	-2479.40%	―	―	65.27%

* Healthcare Sector Average

Performance Comparison

SE:GABA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:GABA	Gabather AB	0.02	-0.01	-31.03%
SE:CAMX	Camurus AB	737.00	93.50	14.53%
SE:ORX	Orexo AB	1.04	-16.53	-94.08%
SE:ALZCUR	AlzeCure Pharma AB	6.68	4.92	279.55%
SE:BIOA.B	BioArctic AB Class B	314.00	20.94	7.14%
SE:SANION	Saniona AB	12.00	-3.44	-22.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026

Gabather AB AI Stock Analysis